"The ‘Fit for Purpose Flow Cytometry Assay Validation’ is the Analytical Performance Package (APP) that management has been alluding to as the critical set of experiments required to demonstrate that LymPro is a commercial-grade test with required reproducibility. Amarantus believes this initial work at ICON will cost less than $150,000 and data should be returned to the company in 6 to 8 weeks. We note that Amarantus is maintaining all intellectual property rights to LymPro at the current time. The agreement with ICON is simply a services agreement that gets the ball rolling on the CLIA process. This services agreement extends over four years and covers LymPro’s central laboratory requirements under CLIA. We note that under CLIA, only one laboratory facility can run a Laboratory Developed Test, so if once LymPro is cleared under CLIA ICON has meaningful upside as the contracted lab to run the test for Amarantus."
This is from Zack's. AMBS is paying ICON to set up Lympro. If this was a blockbuster test, the lab companies would have been busting down the doors to get to Lympro, AND they would have gotten main stream press coverage.
The coverage that they got from JN was farcical. JN is a paid talking head, willing to spew the company propaganda.
I finally took the time to get the reference, someone told me the other day that ICON paid AMBS, it is the other way around. Oh.
So, Lympro will not be much for a long time, and the Eltoprazine study will not be starting this year. Its starting date will depend on first getting a principal investigator and then getting the Principal to get the study past the IRBs at various institutions. And then there is the issue of grants. The company may have the money to pay for this, but if they cannot get a grant, it speaks to the PD community's urgency to do this study.
The truth is incontrovertible. Malice may attack it, ignorance may deride it, but in the end, there it is.
Winston Churchill
